Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020205644 - CANCER BIOMARKERS FOR DURABLE CLINICAL BENEFIT

Publication Number WO/2020/205644
Publication Date 08.10.2020
International Application No. PCT/US2020/025497
International Filing Date 27.03.2020
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • BIONTECH US INC. [US]/[US]
Inventors
  • SRINIVASAN, Lakhshmi
  • TING, Ying Sonia
  • BUSHWAY, Meghan Elizabeth
  • BALOGH, Kristen
  • SCHERER, Julian
Agents
  • GHOSH, Sanjukta
Priority Data
62/826,81329.03.2019US
62/914,76714.10.2019US
62/986,41806.03.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CANCER BIOMARKERS FOR DURABLE CLINICAL BENEFIT
(FR) BIOMARQUEURS DU CANCER POUR UN BIENFAIT CLINIQUE DURABLE
Abstract
(EN)
The present disclosure concerns methods of treating cancer with neoantigenic peptides such that durable clinical benefits are obtained, and compositions and methods for determining whether DCB can be predicted or assessed for a patient to be treated with a therapeutic comprising neoantigen.
(FR)
La présente invention concerne des méthodes de traitement du cancer avec des peptides néo-antigéniques de sorte à obtenir des bienfaits cliniques durables (DCB), et des compositions et des méthodes pour déterminer si le DCB peut être prédit ou évalué pour un patient à traiter avec un agent thérapeutique comprenant un néo-antigène.
Latest bibliographic data on file with the International Bureau